Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
Abstract
Tocilizumab is a monoclonal antibody that interrupts interleukin-6 signalling, reducing downstream effects on inflammation and the innate immune response. It was shown to reduce mortality in patients with severe or critical coronavirus disease 2019 (COVID-19). Pregnant and breastfeeding people were largely excluded from clinical trials and hence, the extent to which results can be applied to these populations is not clear.To synthesize published...
Paper Details
Title
Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
Published Date
Jan 1, 2022
Volume
28
Issue
1
Pages
51 - 57
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History